About Anelixis Therapeutics
Anelixis Therapeutics is a company based in Cambridge (United States) founded in 2013 was acquired by Eledon in September 2020. Anelixis Therapeutics has raised $12.86 million across 5 funding rounds from investors including Eledon and BVF Partners. Anelixis Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Anelixis Therapeutics
Anelixis Therapeutics has successfully raised a total of $12.86M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anelixis Therapeutics
Anelixis Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eledon and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed.
|
Locked | Locked | Locked |
Investor details for Anelixis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anelixis Therapeutics
Investment portfolio details for Anelixis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anelixis Therapeutics
Detailed financials for Anelixis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anelixis Therapeutics Comparisons
Peer comparison for Anelixis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anelixis Therapeutics
Anelixis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Anelixis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anelixis Therapeutics
Complete news archive for Anelixis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anelixis Therapeutics
Anelixis Therapeutics was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Anelixis Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Anelixis Therapeutics is a funded company, having raised a total of $12.86M across 5 funding rounds to date.
Anelixis Therapeutics, a subsidiary of ALS Therapy Development Institute (ALS TDI), is focussed on developing drugs for Amyotrophic lateral sclerosis (ALS). It currently has 2 clinical programs targeting the CD40, Tumor Necrosis Factor (TNF) and superoxide dismutase (SOD1) which play a role in the pathogenesis of ALS. In addition to the clinical assets, it has issued patents for the method of treatment of neurodegenerative diseases by targeting CD40 and the targeting of CD8 T-Lymphocytes to treat neurodegenerative diseases.
Anelixis Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Anelixis Therapeutics has 2 investors. Key investors include Eledon, and BVF Partners.